Literature DB >> 1115749

Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy.

A D Steinberg, M C Gelfand, J A Hardin, D T Lowenthal.   

Abstract

Female NZB/W mice develop a disease closely resembling human systemic lupus and serve as an animal model for therapeutic studies. Several previous studies have demonstrated the efficacy of different immunosuppressive drug regimens in the therapy of glomerulonephritis in NZB/W mice. After the onset of immune complex deposition, treatment with intermittent high doses of cyclophosphamide or daily low doses of the combination of cyclophosphamide, azathioprine, and methylprednisolone has been effective. The present study was designed to compare such effective regimens in mice early in the course of their renal disease versus mice late in the course of glomerulonephritis. One to three injections of high-dose cyclophosphamide during active immune complex deposition and early histologic changes were significantly effective in prolonging survival, whereas treatment late in the course of glomerulonephritis was less effective. Even more striking was the result of low-dose combination therapy. Daily treatment with cyclophosphamide, azathiprine, and methylprednisolone (C + A + M) effectively prolonged survival when started in mice 5 months old, but was of no benefit when started in those 8 months of age. In a concluding experiment, older mice were selected on the basis of degree of renal disease and studied with regard to proteinuria and survival. Those with mild renal disease responded to daily treatment for 6 months with C + A + M at 1 mg/kg of each drug, whereas those with advanced renal disease at the onset of therapy did not benefit.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1115749     DOI: 10.1002/art.1780180102

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Therapeutic effect of beta-[1-phenyl-5-bis(beta-chloroethyl)-amino-benzimidazolyl-(2)-DL-alanin (ZIMET 3164) on immune complex nephritis of NZB hybrid mice.

Authors:  J Güttner
Journal:  Agents Actions       Date:  1979-12

2.  Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice.

Authors:  K Himeno; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  The effect of chronic daily cyclophosphamide administration on established antibody responses.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

4.  Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease.

Authors:  D M Klinman
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

5.  Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation.

Authors:  D L Garcia; H G Rennke; B M Brenner; S Anderson
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

6.  The differential effects of cyclophosphamide and 6-mercaptopurine on the renal disease and skin immunoglobulin deposits of the NZB-NZW F1 hybrid mice.

Authors:  E R Hurd; J N Gilliam; M Ziff
Journal:  Agents Actions       Date:  1976-02

7.  A pharmacologic study of the relationship between lymphocyte function and surface antigen expression.

Authors:  M L Bliven; A C Cunningham; I G Otterness
Journal:  Agents Actions       Date:  1988-08

8.  Cyclophosphamide and 15(S)-15 methyl PGE1 correct the T/B lymphocyte ratios of NZB/NZW mice.

Authors:  D Girard; R M Aloisi; M L Bliven; A C Cunningham; I G Otterness
Journal:  Agents Actions       Date:  1990-03

9.  Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice.

Authors:  J D Prickett; D R Robinson; A D Steinberg
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

10.  Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study.

Authors:  A J Swaak; L W Statius van Eps; L A Aarden; T E Feltkamp
Journal:  Clin Rheumatol       Date:  1984-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.